Cite
HARVARD Citation
Buonomo, A. et al. (2018). Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert opinion on drug safety. 17 (7), pp. 709-717. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Buonomo, A. et al. (2018). Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert opinion on drug safety. 17 (7), pp. 709-717. [Online].